Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Net Cash Flow (2020 - 2025)

Barinthus Biotherapeutics' Net Cash Flow history spans 6 years, with the latest figure at -$4.2 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 131.07% year-over-year to -$4.2 million; the TTM value through Dec 2025 reached -$47.6 million, down 71.89%, while the annual FY2025 figure was -$47.6 million, 71.89% down from the prior year.
  • Net Cash Flow reached -$4.2 million in Q4 2025 per BRNS's latest filing, up from -$10.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $113.5 million in Q1 2021 to a low of -$20.2 million in Q4 2021.
  • Average Net Cash Flow over 5 years is $1.4 million, with a median of -$10.8 million recorded in 2022.
  • The largest YoY upside for Net Cash Flow was 8883.03% in 2021 against a maximum downside of 296.52% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$20.2 million in 2021, then soared by 43.21% to -$11.4 million in 2022, then tumbled by 68.99% to -$19.3 million in 2023, then soared by 170.55% to $13.6 million in 2024, then plummeted by 131.07% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Net Cash Flow are -$4.2 million (Q4 2025), -$10.3 million (Q3 2025), and -$18.1 million (Q2 2025).